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Calcium acetate as phosphate binder
Introduction
In chronic renal failure, phosphate retention contrib-
utes significantly to the development of secondary
hyperparathyroidism and renal osteodystrophy.1 Be-
cause of the relatively poor dialysis clearance of
phosphate and the ubiquitous presence of phosphate
in the diet, phosphate binders are needed in 90% to
95% of long-term dialysis patients to achieve a
satisfactory phosphate level.2 Aluminium salts have
been efficacious binders of intestinal phosphorus but
are now unpopular because of the risk of aluminium
toxicity. Calcium carbonate has been widely used as
a phosphate binder3,4; however, it is only modestly
potent in the binding of phosphorus, and the risk of
hypercalcaemia has limited the dose one can use to
bring the serum phosphate to a satisfactory level. Mai
et al compared the effectiveness of calcium acetate and
calcium carbonate as phosphate binders in haemo-
dialysis patients using the one-meal gastrointestinal
wash-out technique, and found that equivalent doses
of calcium acetate bound twice as much phosphorus
as calcium carbonate.5 Clinical studies of haemodial-
ysis patients confirm the effectiveness of calcium
acetate as a phosphate binder.6-8 Nevertheless, studies
of calcium acetate as a phosphate binder in peritoneal
dialysis patients have rarely been reported. The cur-
rent study investigates whether calcium acetate has a
similar effectiveness to calcium carbonate as phosphate
binders in Chinese patients who are undergoing con-
tinuous ambulatory peritoneal dialysis (CAPD).
Subjects and methods
The study included CAPD patients from the divisions
of nephrology at the Queen Mary and Tung Wah
hospitals who had been on a constant dose of calcium
carbonate (Os-Cal chewable tablet; elemental calcium,
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500 mg/tablet; Marion Merrell Dow Inc., Cincinnati,
Ohio, USA) and who had stable serum biochemistry
(with or without the use of low calcium dialysate) 3
months prior to the study, and a serum phosphate level
≥1.44 mmol/L. The dose of elemental calcium given
in this form ranged from 500 to 3000 mg/day (1 to 6
tablets/day). The following were excluded from the
study: patients who were receiving aluminium hydrox-
ide or sucralfate in addition to calcium carbonate as
phosphate binder; patients who required antacids for
peptic ulceration; those who were scheduled for a
living related transplant or parathyroidectomy within
the previous 3 months; those whose calcitriol dose had
been adjusted within the previous 3 months; and those
with a history of drug non-compliance. Consents were
obtained from all patients before the study.
Patients recruited for the study were given calcium
acetate (Nephrex; elemental calcium, 152 mg/tablet;
Fisons Pharmaceuticals, New South Wales, Australia)
in place of calcium carbonate, with an initial dose of
two thirds of the previous dose of elemental calcium.
The dose chosen was based on the tablet size of
the calcium acetate and on studies reporting that
the equivalent phosphate binding dose of elemental
calcium in calcium acetate in haemodialysis patients
is approximately half of that in calcium carbonate.9,10
The dose of calcium acetate was adjusted to achieve a
serum phosphate level between 1.44 and 1.92 mmol/L
and serum calcium level between 2.1 and 2.6 mmol/L.1
The doses of all other drugs given remained the
same as before the study, and the diet and frequency
of peritoneal exchanges were kept constant. The
incidence of hypercalcaemia, defined as a corrected
serum calcium level ≥2.85 mmol/L, was noted during
the study period.  Patients who had persistent hyper-
calcaemia despite adjusting the dosage of calcium
acetate and using low calcium dialysate, and those who
could not tolerate either calcium carbonate or calcium
acetate were withdrawn from the study.
Patients were followed up every 2 weeks for the
first month and then monthly for the next 2 months.
The serum urea, creatinine, albumin, calcium, phos-
phate, and alkaline phosphatase levels were measured
each time.  The intact parathyroid hormone level was
measured before and at the end of the 3-month study.
The serum calcium level was corrected for changes in
the serum albumin level using the following formula:
corrected serum calcium in mmol/L=measured serum
calcium level+([41–serum albumin in g/L]x0.025).11
The incidence of gastrointestinal upset was also
noted. Subjective patient acceptance was scaled on a
4-point system: 0=withdrawal from study because of
Table 1. Clinical details of the study group
Patients, n=18
No. (%)
Sex
   male 10 (55.5)
   female 8 (44.4)
Type of dialysate received
   normal calcium 12 (66.7)
   low calcium 6 (33.3)
No. of dialysis exchanges per day
   3 shifts 16 (88.9)
   4 shifts 2 (11.1)
Patients receiving calcitriol 7 (38.9)
Causes of renal disease
   unknown 9 (50.0)
   chronic glomerulonephritis 3 (16.7)
   systemic lupus erythematosus 2 (11.1)
   diabetic nephropathy 2 (11.1)
   polycystic kidney disease 2 (11.1)
intolerance, 1=preference for previous medication,
2=no preference, 3=preference for study medication.
The paired t test or the Wilcoxon signed rank test were
used where appropriate for statistical comparison.
Statistical results with a probability level of P<0.05
were considered significant. Data are expressed as
mean±standard error of the mean (SEM).
Results
Twenty CAPD patients were recruited and 18 patients
completed the study. One patient withdrew from the
study after 2 weeks because of intolerance to calcium
acetate. Another patient took the wrong dose of cal-
cium acetate and developed hypercalcaemia. These
two patients were excluded from the analysis. The
mean age of the 18 patients was 42.7 years (range,
25.1-74.0 years) and the mean duration of CAPD was
44.8 months (range, 2.6-98.1 months). The clinical
features of the study population are shown in Table 1.
There were no significant differences between
the pre-study and study levels of serum phosphate,
corrected serum calcium, serum alkaline phosphatase,
or calcium phosphate product (Table 2). There was
also no significant difference in the serum parathyroid
hormone levels that were measured before the study
and at 12 weeks (122±31 versus 124±26 ng/L; P=0.97)
[Fig 1]. Three patients developed a total of five
episodes of hypercalcaemia during the start of the
study and needed a reduction in the dose of calcium
acetate. There were no changes in the diet, type of
dialysate or dose of calcitriol throughout the study.
There were also no significant changes in levels
of serum urea (25.8±1.0 versus 27.0±2.4 mmol/L;
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P=0.19) and creatinine (1127.6±44.4 versus 1152.4±
39.0 µmol/L; P=0.54) before and during the study.
The dose of elemental calcium in the form of
calcium acetate that was needed to achieve similar
phosphate control at 3 months was 65.6% of that in
calcium carbonate. The mean dose of elemental
calcium was 802±83 mg/day in the form of calcium
acetate, compared with 1222±147 mg/day in the form
of calcium carbonate (Fig 2).
Four (22.2%) of the 18 patients who completed
the study developed gastrointestinal upset with the
calcium acetate treatment, which included constipa-
tion, abdominal discomfort, and dyspepsia. Eight
Table 2. Plasma parameters after conversion from calcium carbonate to calcium acetate treatment
Baseline* 2 weeks 4 weeks 8 weeks 12 weeks
Phosphate 1.81 1.78 1.77 l.81 l.89
(mmol/L) ±0.04 ±0.06 ±0.08 ±0.07 ±0.06
Corrected calcium 2.54 2.49 2.53 2.53 2.57
(mmol/L) ±0.04 ±0.04 ±0.05 ±0.04 ±0.03
Calcium phosphate 4.60 4.45 4.49 4.58 4.87
product ±0.15 ±0.99 ±0.24 ±0.20 ±0.18
Alkaline 64.75 65.72 63.78 65.61 69.94
phosphatase (U/L) ±4.17 ±4.86 ±3.78 ±4.03 ±3.77
*Baseline values are at week 0, during calcium carbonate treatment; all values are mean±SEM
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Fig  1. Levels of parathyroid hormone at start of study
and after 12 weeks of calcium acetate treatment
The two circles with vertical bars represent the mean±SEM
at the two time points. Week 0 represents calcium carbonate
treatment; thereafter, calcium acetate was given.
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Fig 2. Doses of elemental calcium needed for phosphate
control
Bars represent the mean±SEM. Week 0 represents calcium
carbonate treatment; thereafter, calcium acetate was given.
(44.4%) patients expressed a preference for the previous
calcium carbonate treatment, eight (44.4%) patients
preferred calcium acetate, and two (11.1%)  patients had
no preference.
Discussion
This study has shown that calcium acetate is an
effective phosphate binder in renal failure patients
who are maintained with CAPD. Calcium acetate
achieved similar phosphate control to calcium carbon-
ate with 65.6% of the latter’s dose of elemental cal-
cium. Despite the lower dose of elemental calcium
ingested, however, hypercalcaemia was a problem.
While there were no cases of hypercalcaemia before
the study, five episodes occurred during the study. This
observation contradicts the expectation of a decrease
in the incidence of hypercalcaemia as based on
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calcium absorption data published by Mai et al.5 Our
results concur with those of Moriniere et al9 and Ben
Hamida et al10 which show that the use of calcium
acetate when compared with calcium carbonate does
not decrease the incidence of hypercalcaemia in
haemodialysis patients. The reason for the conflicting
results is not clear. The data from Mai et al5 are from
studies using a gastrointestinal wash-out technique,
and extrapolation of the results to an in vivo situation
may not be valid. Disagreement between the calcu-
lated and actual daily calcium absorption data have
also been obtained by Clarkson.12 Moreover, the higher
solubility of calcium acetate at an alkaline pH of
the intestine means that more free calcium is available
for absorption from calcium acetate than from calcium
carbonate.13 This may explain why there is no decline
in the incidence of hypercalcaemia in renal failure
patients using calcium acetate. Whether differences
between using haemodialysis and CAPD contribute
to differential gastrointestinal calcium absorption
awaits further studies.
Approximately one quarter of the patients devel-
oped gastrointestinal upset; in contrast, all patients
tolerated calcium carbonate treatment well.  There were
no particular preferences for either calcium acetate or
calcium carbonate. The preparations of calcium acetate
used in this study, however, contained only 152 mg of
elemental calcium per tablet; patients needed to take
double the number of tablets compared with calcium
carbonate to achieve comparable phosphate control.
This was an inconvenience and contributed to diffi-
culty in compliance, especially in patients who were
already receiving multiple medications. In addition,
at the current price the cost of the necessary dose
of calcium acetate to achieve equivalent phosphate
binding was four times that of calcium carbonate.
Thus, the routine use of calcium acetate as a phos-
phate binder would not be cost-effective.
In conclusion, calcium acetate is an effective
phosphate binder in CAPD patients but its clinical
superiority over calcium carbonate cannot be demon-
strated in this study. Routine use of calcium acetate
is therefore not recommended, but it may provide an
alternative choice for patients who cannot tolerate
calcium carbonate for reasons other than hyper-
calcaemia.
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